CNS Response, Inc. announced that it has received a patent from the U.S. Patent and Trademark Office. The patent, numbered 7,489,964 and titled “Electroencephalography Based Systems and Methods for Selecting Therapies and Predicting Outcomes”, extends application of rEEG® technology to novel methods that can expand indications for CNS pharmaceuticals.

“One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications,” commented CNS Response CEO Len Brandt. “With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG technology not only to physicians treating behavioral illness, but also to the pharmaceutical industry including ways described in this patent.”

The awarded patent presents novel use of CNS Response protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG computer analysis. One demonstration of patient benefit is demonstrated in the four-year, rEEG-guided treatment of anorexia/bulimia study reported by James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs. In the study of 13 severely ill, previously hospitalized patients, 13 of the 14 medications successfully used did not carry indications for eating disorders.

A second patient benefit was shown in a study for treating resistant depression by Charles DeBattista, D.M.H, M.D., Professor of Psychiatry and Behavioral Sciences, Director of Depression and Psychopharmacology Clinics, Stanford University School of Medicine, Palo Alto, Calif., where most of the patients successfully treated had regimens involving medications not indicated or traditionally used in treatment of depression.

“Both of these recent studies demonstrated that there is a significant opportunity for expansion of psychotropic indications, and that rEEG can guide that expansion,” added Mr. Brandt. “New indications for FDA approved drugs can be among the greatest return on investment for pharmaceutical companies.”